Welcome to our dedicated page for Artivion news (Ticker: AORT), a resource for investors and traders seeking the latest updates and insights on Artivion stock.
Artivion, Inc. reports developments for a cardiac and vascular surgery medical device business focused on aortic disease. Recurring updates cover aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, along with preservation services for cardiac and vascular tissues and product sales across international markets.
Company news also includes quarterly and annual financial results, clinical presentations tied to NEXUS and AMDS aortic-disease programs, FDA and PMA-related regulatory developments, financing and capital-structure actions, investor conference participation, and governance matters. The company’s disclosures often connect revenue trends to stent grafts, On-X, BioGlue, preservation services, and other product categories used by cardiac and vascular surgeons.
Artivion (NYSE:AORT) closed the acquisition of Endospan, following April 2026 FDA PMA approval of the NEXUS Aortic Arch System, described as the first off-the-shelf endovascular solution for high-risk aortic arch disease. The deal includes a $175M purchase price (less prior loan offsets) plus up to $200M contingent on U.S. NEXUS commercial performance over two years.
The transaction adds NEXUS and its custom configurations (NEXUS DUO, NEXUS TRE) to Artivion’s existing AMDS and ARCEVO LSA offerings, expanding its global aortic arch portfolio across EMEA, Europe, Asia-Pacific and Latin America.
Artivion (NYSE:AORT) completed the acquisition of endovascular aortic arch specialist Endospan, developer of the NEXUS Aortic Arch System. The $135 million upfront net purchase price was funded using a previously drawn $150 million delayed draw term loan, with additional performance-based consideration possible.
The NEXUS branched endovascular stent graft system received FDA PMA approval in April 2026. Artivion has distributed NEXUS in EMEA since 2019 and, according to the company, this deal completes its three-part aortic arch portfolio alongside AMDS and ARCEVO LSA, adding a pipeline of next-generation arch technologies.
Artivion (NYSE: AORT) reported Q1 2026 revenue of $116.3M (GAAP, +18% YoY; +12% non-GAAP constant currency), net income of $1.4M ($0.03/share), and adjusted EBITDA of $22.1M (+26% YoY). The company received FDA PMA for NEXUS and exercised its option to acquire Endospan for $135M, expecting close in Q2 2026. Full-year 2026 guidance was lowered to $480–496M revenue and $100–107M adjusted EBITDA; NEXUS U.S. sales are expected to be negligible in 2026.
Artivion (NYSE:AORT) will release Q1 2026 financial results on May 7, 2026 after market close, followed by a teleconference and live webcast at 4:30 p.m. ET.
Pat Mackin, Chairman, President and CEO, will host the call with a Q&A. Replay and webcast will be available via the Investors section of the Artivion website and by telephone replay.
Artivion (NYSE:AORT) announced U.S. FDA approval of the NEXUS Aortic Arch System on April 7, 2026, developed by partner Endospan. The approval allows Artivion to exercise an option to acquire Endospan within 90 days.
Artivion has a $150 million delayed draw term loan in place to fund a potential acquisition. FDA support comes from the TRIOMPHE IDE trial showing 90% patient survival from lesion-related death, 90% freedom from disabling stroke at 1 year, and 98% freedom from reintervention due to endoleaks at 1 year.
Artivion (NYSE:AORT) will participate virtually in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference with a fireside chat on March 17, 2026 at 9:20 a.m. ET.
According to Artivion, the live webcast will be accessible on the company's Investors page and an archived copy will be available for 90 days.
Artivion (NYSE: AORT) reported strong Q4 and full-year 2025 results, with GAAP revenue $116.0M Q4 and $441.3M for 2025. Adjusted revenue was $118.3M Q4 and $443.6M FY (adjusted constant currency growth 18% Q4, 13% FY). GAAP net income was $2.4M Q4 and $9.8M FY; adjusted EBITDA was $22.7M Q4 and $89.6M FY. Company filed final PMA module for AMDS Hybrid Prothesis and reported positive IDE clinical data for Endospan NEXUS TRIOMPHE and AMDS PERSEVERE.
Artivion (NYSE: AORT) will present new clinical data at the 62nd Society of Thoracic Surgeons meeting showing favorable outcomes from two IDE trials. NEXUS TRIOMPHE (n=94) reported 94% survival from lesion-related death and 91% freedom from disabling stroke at 1 year. AMDS PERSEVERE (n=93) showed persistent aortic remodeling, zero distal anastomotic new entry tears through 2 years, and minimal additional morbidity.
Artivion (NYSE: AORT) will release fourth quarter 2025 financial results on Thursday, February 12, 2026 after market close.
The company will host a teleconference and live webcast at 4:30 p.m. ET with CEO Pat Mackin, followed by Q&A; replay will be available about one hour after the event. Earnings materials and the webcast/replay will be posted in the Investors section at www.artivion.com.
Artivion (NYSE: AORT) reported strong Q3 2025 results on Nov 6, 2025: revenue $113.4M (+18% GAAP; +16% non-GAAP constant currency vs Q3 2024) and net income $6.5M ($0.13/diluted). Adjusted EBITDA rose 39% to $24.6M. Commercial growth drivers included stent grafts +38% and On-X +25% (year-over-year).
Corporate updates: first patient enrolled in ARTIZEN IDE trial for Arcevo, favorable AMDS clinical data presented, and refinancing that extends credit maturity to 2031 plus a $150M delayed-draw term loan. Full-year 2025 guidance midpoints were raised for constant-currency revenue and adjusted EBITDA.